The efficient design of experiments (i.e., selection of experimental doses and allocation of animals) is important to establishing dose-response relationships in toxicology studies. The proposed procedure for design of experiments is distinct from those in the literature because it is able to adequately accommodate the special features of the dose-response data, which include non-normality, variance heterogeneity, possibly nonlinearity of the dose-response curve, and data scarcity. The design procedure is built in a sequential two-stage paradigm that allows for a learning process. In the first stage, preliminary experiments are performed to gain information regarding the underlying dose-response curve and variance structure. In the second stage, the prior information obtained from the previous stage is utilized to guide the second-stage experiments. An optimization algorithm is developed to search for the design of experiments that will lead to doseresponse models of the highest quality. To evaluate model quality (or uncertainty), which is the basis of design optimization, a bootstrapping method is employed; unlike standard statistical methods, bootstrapping is not subject to restrictive assumptions such as normality or large sample sizes. The design procedure in this paper will help to reduce the experimental cost/time in toxicology studies and alleviate the sustainability concerns regarding the tremendous new materials and chemicals.
INTRODUCTION
This work is primarily motivated by the rising need to assess the risks resulting from human exposure to various nanomaterials. With the rapid development of nanotechnology, nanomaterials find increasing applications in the energy, 1,2 environment, [3] [4] [5] and biomedical engineering sectors. 6, 7 Workers may be directly exposed to nanomaterials during manufacturing, handling, and transport of nanomaterials, and end-users may uptake nanomaterials due to the release of nanomaterials from consumer products. Therefore, risk assessment of a large variety of nanomaterials plays a critical part to ensure the safe and sustainable development of nanotechnology.
One of the most fundamental steps in assessing the risk of a nanomaterial (or any other substance) is to understand and properly characterize its dose-response relationship. 8, 9 To estimate such relationships, biological experiments need to be performed at different dose levels to observe the corresponding bioactivity responses of animals. Because of costs, ethics, or other limitations on resources or time, sample sizes are usually restricted and efficient use of available resources is critical. Thus, the design of experiments (DOE), i.e., the selection of experimental doses and the allocation of animals, plays an important role in the success of dose-response modeling.
The DOE for efficient dose-response modeling is challenging due to the following two major reasons. First, the dose-response curves may well be nonlinear, [10] [11] [12] and thus, the optimum design of experiments depends on the true underlying curves to be estimated, which is unfortunately unknown. 13, 14 Second, with constrained resources, typically the amount of data allowed to be collected are not only relatively scarce and highly variable but almost certainly possess different variability across the dose range being investigated. 15 These special features of dose-response data are not adequately addressed in the existing DOE methods.
designs, which will be referred to as the traditional design, usually involve equally spaced doses on a linear or log scale and equal allocation of animals and may well lead to inefficient use of resources. Some researchers 8, [18] [19] [20] [21] recognized the nonlinearity of doseresponse relationships and resorted to standard optimum design techniques 13 to approach the DOE issues. These works relied on the assumption of constant variance throughout the dose range, which typically does not hold in reality. There is also some literature by statisticians that investigated the optimum design for statistical modeling in general while taking into account the existence of variance heterogeneity. In this stream of work, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] the authors usually had a particular interest in pursuing analytical solutions under various simplistic assumptions. For instance, DasGupta et al. 23 derived the optimal designs under normal prior conditions for the simple linear model when the error variance is a power function or an exponential function of the mean. These results, though theoretically appealing, are often impractical for toxicology studies where the required assumptions no longer hold.
The objective of this work is to develop a DOE procedure, which is statistically valid and practically useful, to guide the dose selection and animal allocation in biological experiments for the efficient generation of dose-response relationships. Through the following three major efforts, we intend to provide a new DOE method that adequately accommodates the nonlinear nature of dose-response curves and variance heterogeneity of toxicity data. (i) The proposed procedure is built in a two-stage paradigm. In the first stage, a batch of preliminary experiments are performed to gain information regarding the underlying dose-response curve and variance structure. In the second stage, the prior information obtained from the previous stage is utilized to guide the second batch of experiments. Compared to the traditional once-and-for-all designs, such a sequential design is known to lead to improved model estimation when a total sample size is given or to bring savings in samples if a certain model quality is desired. (ii) For the design of the second batch of experiments, a new algorithm (Algorithm 3) is developed to effectively search for the optimum design that will lead to dose-response models of the highest quality. (iii) To evaluate the model quality, which is the basis of design optimization in (ii), bootstrapping, as opposed to standard statistical methods, is employed. Bootstrapping is a computationally intensive resampling method and is not subject to restrictive assumptions such as normality or large sample sizes.
The remainder of this paper is organized as follows. The Statistical Modeling and Inference section details the modeling/inference issues involved in the estimation of dose-response curves and provides the building blocks of the two-stage DOE procedure. The procedure, which aims at achieving an efficient experimental design, is described in the Two-Stage Procedure section. In the Empirical Evaluation section, a simulation study is performed to evaluate the efficiency of the proposed DOE procedure by comparing it with the traditional design currently used in toxicology studies. The Summary section summarizes the findings of this paper and discusses future work.
STATISTICAL MODELING AND INFERENCE
In this section, we present the statistical modeling and inference methods for estimating the dose-response relationship based on a given set of experimental data. These methods provide the necessary basis for the DOE procedure in the Two-Stage Procedure section.
Heteroscedastic Dose-Response Model
Let Y be the continuous random response of a biological experiment. We represent the doseresponse curve by a general model where x denotes the dose level and θ the p × 1 vector of unknown parameters. The random variable Y is related to its mean by the relationship where ε is the error term. The feasible region of the dose level x is typically specified by (1) The lower and upper bounds, x L (x L ≥ 0) and x U (x U > x L ), are specified by the experimenters based on the substance of interest.
The mean response model f(x, θ) can take any functional forms that are differentiable and monotonic. Example models include linear, polynomial, power (EPA Benchmark Dose Software 33 ), and the four-parameter logistic model widely used in the literature. 34, 35 In the empirical study of this paper, the following functional form is used for illustration (2) The error ε is assumed independent across individual observations, and to be expressed as (3) where σ is a scale parameter; e is a random error following the standard normal distribution; h describes how the standard deviation of ε depends on the mean response f(x, θ); and γ denotes the vector of unknown parameters involved in model h.
The formulation of the error (3) is able to model a wide range of error heterogeneity commonly encountered and has been extensively employed in the literature. [35] [36] [37] [38] In this work, a specific functional form as given below is assumed for the variance model h(f(x,θ),γ) of the empirical example in the Empirical Evaluation section (4) Wang et al. Page 4 where γ is the unknown parameter. The form (eq 4) has been popularly used in toxicology and pharmacology studies. [34] [35] [36] 38, 39 
Estimation of Dose-Response Model and Benchmark Dose (BMD)
Given a data set {(x i ,y i ),i = 1,...,I} with a sample size of I, how do we estimate the doseresponse models in the presence of variance heterogeneity? Preliminary data analysis as that suggested by Carroll and Ruppert 36 need to first be performed to select specific functional forms for f(x,θ) and h(f(x,θ),γ), which may turn out to be eqs 2 and 4, respectively, for examples. Then, the iteratively reweighted least-squares (IRLS) framework 36 is adopted to fit the models. The IRLS algorithm (Algorithm 1) is described using the notations of our dose-response modeling.
With the estimated dose-response model , the expected toxicity response can be obtained as at any exposure level
The model also allows for the estimation of exposures at responses of different severities; such an exposure level is referred to as benchmark dose (BMD) and is of particular interest in toxicology because it assists in setting the safety standard for the substance being investigated.
The BMD is the dose that corresponds to a specified level of adverse response called the benchmark response (BMR). The BMR can be defined as a relative change in the mean response from the control mean or as an absolute level. 33, 40 Either definition can be selected based on the knowledge available regarding the substance's adverse effects, and in modeling, the BMR defined in one way can be easily converted to that defined in the other way. For illustration in this work, we let the BMR be a preselected absolute response. Given the fitted dose-response model , the BMD can be estimated as (5) where f −1 represents the inverse function of f.
Quantifying Estimation Uncertainty
In this part, we discuss the uncertainty quantification (or statistical inference issues) for the dose-response modeling. The following two types of uncertainties/variabilities are of primary interest.
• the variance of the estimated parameters in the fitted dose-response model .
Clearly, determines the quality of the estimated dose-response model . With the increasing of experimental data (sample size), will decrease and is directly associated with the D-optimum design criterion in the DOE literature. 13 • , the variance of the estimated BMD.
As shown in eq 5, is a function of the pre-specified BMR, which is deterministic, and the estimated parameter , which is subject to uncertainties. Hence, is affected by both the BMR value and . For certain BMR, directly relates to the safety standard of a substance. With , a confidence interval (CI) can be formed for the BMD, and it has a clear and practically meaningful interpretation. In toxicology studies, the lower bound of the CI is referred to as BMDL and represents the lower confidence limit on the dose that would result in the required response BMR 33 In light of the discussions above, measures the overall quality of the dose-response model, whereas not only depends on the model quality but is also associated with a particular BMR. Depending on the purpose of a study, either of these two variabilities can serve as the criterion to drive the optimal design of experiments. Either criterion can well fit into our two-stage DOE procedure.
As will be seen later in Algorithm 3 (Two-Stage Procedure section), the prerequisite of using or as a design criterion is the ability to evaluate these variabilities for a candidate design. This ability can be derived from the evaluation of or for a given sample data set, which will be discussed in the remainder of this subsection.
Bootstrap Resampling Algorithm-As mentioned in the Introduction section, standard statistical inference methods are not able to provide valid variability estimates for doseresponse modeling. Hence, we use a bootstrapping resampling method to evaluate and . The bootstrap is a data-based simulation method for statistical inference. 41 The basic idea of bootstrap is to use resampling (sampling from the sample, obtaining what is called bootstrap samples) to quantify the variability of the estimates of interest. 42 Under the assumptions given in the Heteroscedastic Dose-Response Model subsection, the resampling scheme proposed by Zeng and Davidian 35 is adapted to quantify the uncertainties of the model estimation performed on the given data set {(x i ,y i );i = 1,2,...,I}, and the resampling algorithm is described in Algorithm 2.
Zeng and Davidian 35 recommended setting the resample size to B = 499 based on their empirical experience. Note that M, the assumed number of design points in Input (a) of the algorithm, is allowed to be different from I, the number of real samples {(x i ,y i );i = 1,2,...,I} involved in Input (b). If the purpose of executing Algorithm 2 is solely to quantify the model uncertainties given a real data set {(x i ,y i );i = 1,2,...,I}, then we set M = I. However, in this work, Algorithm 2 is meant to be called by Algorithm 3 (the DOE algorithm in the Two-Stage Procedure section) to evaluate additional candidate design points, and hence, we distinct between M and I with M ≥ I.
Quantifying the Uncertainty of Estimated Model Parameters-Given
obtained from Algorithm 2, the variance-covariance matrix can be estimated as follows 36 (6) where are the estimates obtained from the original data {(x i ,y i );i = 1,2,...,I}.
Quantifying the Uncertainty of Estimated BMD-Recall the expression of BMD (eq 5). With the B fitted models from Algorithm 2, B BMD estimates can be obtained as follows (7) for a pre-specified BMR. On the basis of , is estimated as (8) where is obtained from , and the dose-response model is estimated from the original sample data {(x i ,y i );i = 1,2,...,I}.
The variance estimate can be used to form the one-sided confidence interval (CI) for the BMD 33 at a selected confidence level α. The BMDL (lower bound of the onesided CI) is given as 35 (9) where t α,M-p stands for the 100α th quantile of the student t distribution with M-p degrees of freedom, in which p stands for the number of fitted parameters in the dose-response model.
TWO-STAGE PROCEDURE
The major contribution of this work lies in the development of a new two-stage DOE procedure for dose-response modeling. Compared to standard once-and-for-all designs, sequential (multi-stage) designs typically lead to (i) savings in sample size if model estimates of desired quality (measured by the uncertainty/variabilty of model estimates) are to be achieved or (ii) model estimates of improved quality given a fixed total sample size. 11, 43 Because biological studies are typically performed with restricted sample sizes, the two-stage design procedure in this work is tailored to achieve models of the highest quality with a pre-specified total sample size. It is worth pointing out that the two-stage procedure can be easily adapted to a design procedure that is driven by a desired model quality and not constrained by a pre-specified total sample size; such a procedure may involve multiple (more than two) stages of experiments.
For the two-stage DOE procedure, the inputs are given as 
Input 4 (optional):
BMR, the pre-specified benchmark response level, which is not necessary unless the design criterion is .
The outputs of the procedure include the design of experiments for the N samples; the doseresponse model and the variance model both of which are estimated from the N-sample data set and allow for the BMD estimation; and the uncertainties of the estimates of interest including and if a prespecified BMR is given. Clearly, the key tasks yet to be addressed in Figure 1 are the initial design in Stage I and the design augmentation is Stage II. Both tasks aim at answering the DOE questions in their designated stages, such as at what design points (i.e., dose levels) within the design space [x L ,x U ] should the experiments be carried out and how many replications should be assigned to each design point?
Two alternative notations are used in this paper to represent a design. One is given as (10) Wang
Clearly, the total sample size given by is . Alternatively, a design (10) can be expressed as (11) with being the number of samples. Note that the array may well include the same design points multiple times, which correspond to multiple replications. In the remainder of this paper, both eqs 10 and 11 will be used to refer to a design.
Stage I: Initial Design
At Stage I, N I preliminary samples are to be performed. Given N, the total number of samples available, we recommend setting N I as 1/4-1/2 of N. Guidelines for specifying N I can also be found in Santner et al. 11 Having selected a value for N I , how do we allocate these N I samples? Following the notation in eq 10, the initial design is represented as (12) where D 0 is the number of distinct dose levels.
In this work, assuming that no prior information other than the dose range [x L ,x U ] is available at the initial stage, we specify the initial design as follows. First, the design points are evenly spaced on the original or log scale, as in the traditional designs, and we set and , including lower and upper bounds of the dose range in the design to avoid potential extrapolation, which is considered dangerous in statistical estimation. 44 Second, D 0 , the number of distinct design points, has to be at least four, which is the typical number needed to capture the trend of a dose-response curve.
Third, we have for any d to allow for the detection of variance heterogeneity and for the estimation of the variance model (eq 3). In the absence of any other concerns, we can simply set . For instance, in light of the considerations above, the initial design for the example in the Empirical Evaluation section is specified as (13) given In this work, the dosage range [x L ,x U ] is divided into a relatively large number of equally spaced grid points, and only these grid points are considered as the candidate design points for the design optimization (14) for the following reason. The equally spaced grid points can be chosen in such a way that any two neighboring points are practically different. By restricting the design points to these grid points, the design optimization 14 can avoid providing design points that are numerically but not practically different.
As in eq 14, the N-N I design points are selected to minimize the design criterion subject to two constraints. First, N I samples have already been collected. Second, these N-N I points have to be selected from the predetermined grid points within [x L ,x U ]. As mentioned earlier, depending on the practical need, the design criterion could be , the determinant of the variance-covariance matrix of , or , the variance of for a given BMR. Solving this optimization problem to obtain the best design is challenging. (i) The design criterion in the objective function (eq 14) represents the variability of the model estimates ( or ) obtained from all the experimental data including those collected at first and second stages. However, at the current point of solving eq 14 and designing for second-stage experiments, only first-stage data are available, and there is no closed-form formulation for the objective function. To overcome this difficulty, in Algorithm 3, which aims at solving eq 14, a bootstrapping-based method is developed to numerically evaluate the design criterion and to provide the basis to solve the design optimization. (ii) Determining {x N I +1 ,x N I +2 ,...,x N } simultaneously is difficult due to the high dimension (which is N-N I ) of the decision variables and the large size of the decision space. In light of this, we use a heuristics that adds one design point at a time until all the N-N I points have been found. The algorithm for solving eq 14 is described as follows assuming that is the design criterion. The algorithm can be straightforwardly adapted to the design optimization with being the criterion, as will be explained later.
Algorithm 3 is initiated with the Stage I design , and the first FOR-LOOP iterates to add one design point to the design at a time until all the N-N I design points have been found. At this iteration level, for a given design that already includes N I +k (k = 0,1,...,N-N I -1) points, how do we determine the (N I +k+1) th design point? The answer is the second FOR-LOOP, which iterates to evaluate every grid point; the best grid point is chosen as the (N I +k+1) th design point, and the design D is updated accordingly. Steps (i) and (ii) are the bootstrapping-based methods developed to evaluate each grid point in terms of their additional contribution to the optimization objective, given a to-be-expanded design .
Note that Algorithm 3, which is driven by the design criterion , can be easily modified to solve eq 14 with the criterion being . The only change that needs to be made is to replace Step (ii) by evaluating with eq 6.
Following the additional design {x N I +1 ,x N I +2 ,...,x N } found by applying Algorithm 3, Stage II experiments will be performed for data collection. Lastly, based on all the data collected at both stages with a total sample size of N, statistical modeling and inference will be performed to obtain the final estimation for the dose-response model and the BMD and to quantify the uncertainties on those estimates of interest.
EMPIRICAL EVALUATION
The proposed two-stage design procedure has been evaluated by a simulation study, which is based on sampling through computer experiments whose outputs mimic dose-response data from real experiments. Simulation, rather than real experiments, is employed for the following reasons. First, only in a simulation-based study are the true dose-response models (i.e., the simulation models) available to evaluate the model estimates. Second, the outcome of a design procedure is random due to the randomness of responses; hence, a design procedure needs to be evaluated in a statistical manner based on the outcomes of applying it many times, which is impossible with real experiments. These advantages of simulation will become clear in the Comparison with Traditional Design subsection.
Simulation Models
In this case, the simulation data are generated using the following true dose-response and variance models (16) 
At an arbitrary dose level, say x 0 , a response y 0 is simulated as (18) where ε is a random error provided by a standard normal random number generator. 45 The simulation models (eqs 16 and 17) are derived from the real experimental data in the toxicity study of TiO 2 nanowires. 46 The dose x represents the TiO 2 nanowire dosage in terms of μg/mouse, and the response y is the BAL (bronchoalveolar lavage) PMNs measured in the units of 10 3 /mouse. C57BL/6J male mice were exposed to selected dosages of TiO 2 nanowires, and at seven days post-exposure, whole lung lavage was conducted to obtain the BAL PMN counts.
The true models (eqs 16 and 17) are blind to the two-stage procedure and are only used for two purposes in this study: (i) to generate simulation data that mimic real biological data and (ii) to serve as the true benchmark to evaluate the model estimates obtained from applying the DOE procedure.
Applying the Two-Stage Procedure
For the toxicity study of TiO 2 nanowires, suppose that it is of particular interest to establish the BMD corresponding to a BMR of 177 ( × 10 3 /mouse) for the BALPMN endpoint.
(Recall that the BMR can be defined in different ways that do not affect the application of our methods, and in this paper, we treat the BMR as an absolute level.) How to specify a BMR is beyond the scope of this work, and BMR = 177 is employed for the purpose of illustration.
The two-stage DOE procedure (Figure 1 ) is applied to guide the experiments (that is, the simulation experiments in this empirical study) for the efficient collection of dose-response data, aiming at obtaining a good BMD estimate corresponding to the target BMR = 177. The inputs of the procedure are given as follows:
Input 1: N = 40, the total sample size available. Input 4: BMR = 177: the pre-specified benchmark response.
The criterion in the design optimization (eq 14) is set as accordingly.
Stage I
The initial design with N I = 20 samples was obtained and is given in Table 1 . , the response subject to random errors is generated by plugging the value of x i into eq 18, and the response data are given in Table 2 . From the paired data {(x i ,y i ); I = 1,2,...,20}, the dose-response and variance models are estimated as follows by applying Algorithm 1 (19) (20)
Stage II
The augmented design was determined by applying Algorithm 3 with the following inputs.
(a) The first-stage design with values of the design points given in Table 1 The resulting augmented design turned out to be as given in Table 3 .
Following the augmented design (Table 3) , simulation was performed to obtain the random responses, which are given in Table 4 .
Feeding all the data collected in both stages {(x i ,y i ); I = 1,2,...,40} to Algorithm 1, the doseresponse and variance models were finally estimated as (21) (22) Figure 2 plots the fitted dose-response curve (eq 21), along with the Stage I data depicted by dots and Stage II data depicted by squares.
Comparison with Traditional Design
The results presented above in the Applying the Two-Stage Procedure subsection represent the outcome of applying the two-stage procedure for one time. Because of the random nature of responses, reapplying the procedure will lead to first-stage responses different than those given in Table 2 and first-stage fitted models different than those in eqs 19 and 20. Consequently, the augmented design in Stage II will turn out differently, the final 40 sample data set will be different, and the modeling/inference results will be different.
Also, because of the randomness in responses, every time the same traditional design is applied, a different set of responses will be collected, and hence, different modeling/ inference results will be obtained. The traditional design for this case is given in eq 23 and is the one used for the toxicology study in Porter et al. 46 (23) The two approaches, our two-stage procedure and the traditional design, both have random outputs. The modeling/inference results are subject to the randomness of responses. Hence, these two approaches are compared in a statistical manner as follows.
Each of the two approaches was applied in this case 100 times. As a result, 100 sets of results were obtained for each approach. Because the primary goal of this study is to estimate BMD for BMR = 177, the two approaches are compared in terms of their delivered BMDL (eq 9), the lower bound of the one-sided confidence interval for the BMD.
Specifically, applying the two-stage procedure 100 times leads to 100 data sets; from each data set, the methods (Algorithms 1 and 2) in the Statistical Modeling and Inference section were performed to obtain the BMDL (eq 9). From the 100 data sets, the 100 BMDLs obtained are denoted as (24) In the same way, applying the traditional design (eq 23) 100 times also results in 100 data sets. Performing the statistical modeling and inference on these data sets leads to 100 BMDLs, which are denoted as (25) The true BMD can be easily calculated from the true dose−response simulation model (eq 16), and it turns out to be 24, which is represented by the horizontal line in Figure 3 . The box plots are generated in Figure 3 for the BMDLs (eq 24) obtained from our two-stage procedure (left box) and the BMDLs (eq 25) obtained from the traditional design (right box). A box plot provides the basic information regarding the distribution of a data set (say, the BMDLs in eq 25), with the lower hinge being the 25 th percentile, and the upper hinge being the 75 th percentile of the data. For details of box plots, please refer to McGill et al. 47 Comparing the two boxes in Figure 3 , it is evident that the BMDLs resulting from our procedure are closer to the true BMD and vary over a narrower dose range. In other words, with the same sample size, collecting a data set following the traditional design leads to a BMDL that may be anywhere between the lower and upper adjacent of the right box plot, whereas collecting a data set following the two-stage procedure leads to a BMDL that falls within the much narrower and more accurate range of the left box.
SUMMARY
This work developed a two-stage experimental design procedure. Compared to the commonly used naive designs, our methods lead to dose-response models of higher quality given a limited sample size (or equivalently, leads to smaller sample size for a pre-specified model quality). The methods developed in this paper are able to reduce the experimental cost and time in toxicology studies, alleviate the rising concerns for animal ethics, and accelerate the progress toward quantifying the risk, safety, and health effects of environmental and occupational exposure to any substances (e.g., nanomaterials).
The two-stage procedure goes on the premise that no significant cross-stage variability exists, that is, there is no systematic changes from the first-to the second-stage experiments, and dosage is the dominant factor that accounts for the variability in biological responses. This assumption may well hold for experiments that are performed in the same lab by the same experimenters over a relatively short period and on animals with similar characteristics (say, weight, age, etc.). In our immediate future research, we will propose a design procedure that is able to accommodate cross-stage variability; such variability may stem from different batches of animals, different experimenters, or different research environments/laboratories. For instance, a design question to be addressed may be as follows: Given a certain substance's toxicology data obtained by some other research laboratories, how should we design our experiments so that the integrated data from multisources can provide the most useful information? Answers to such experimental design questions will certainly help to accelerate the toxicology assessment of various substances and to facilitate the integration of multi-source data. Overview of the two-stage procedure. Fitted dose-response model along with the simulation data. Box plots for the BMDLs resulting from the two-design methods. 
Algorithm 1
Inputs: Data set {(x i , y i ), i = 1, . . ., I}
Process:
Step 0: Fit the dose-response model by performing regular (unweighted) least squares regression on the data {(x i , y i ), i = 1, . . ., I}, and denote the fitted model as f ( x, θ (0) ) ; set r = 1.
Step ; g = 1, 2, …, G}, the evenly spaced grid points in [x L , x U ] that serve as the pool of candidate design points; (d) the resampling size B; (e) the pre-specified BMR, which is only needed if Var BMD is the design criterion in (14) . }. Specifically, Formula 
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